Ben Hohn

As the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.

Judith Kulich and Ben Hohn pose the high priority questions that those teams opting to move forward with a launch, or to move forward after a delay, in the face of the COVID-19 pandemic.

Three product launch trends driven by emerging biopharma.